 Dr. Arjomand is founder of Accium BioSciences and is responsible for Accium’s commercial AMS services and operations. He serves as Scientific Director for Accium's AMS-based studies and is responsible for each sponsor's bioanalytical project. Dr. Arjomand obtained his Doctorate in 1998 from the University of California in Davis under the guidance of Dr. Andrew Clifford. He designed and conducted the first human microdosing study using AMS in a joint research effort with Lawrence Livermore National Laboratory (see publications). Prior to co-founding Accium, Dr. Arjomand was Director of Technical Business Development at CombiMatrix Corporation, a publicly traded genomics biotechnology company. As the sixteenth employee hired, Dr. Arjomand co-led the development of commercialization strategies and oversaw the expansion of the company’s DNA chip products into the U.S. and Asian markets. Prior to joining CombiMatrix, Dr. Arjomand was lead technical consultant for chromatography at Bio-Rad Laboratories, a $1B supplier of life science and diagnostics products.
|
